The investigators demonstrated that cholestyramine is an effective binding agent in vitro for porphyrins. A few isolated case reports of treatment of individuals with a cutaneous porphyria suggest that cholestyramine and colestipol effectively remove porphyrins. Hypothesis: orally administered colestipol will effectively reduce sun sensitivity and lower erythrocyte porphyrin concentrations in subjects with erythropoietic protoporphyria (EPP).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Photosensitivity, Assessed by Measuring the Number of Minutes of Sun Tolerance
Timeframe: At 60 days of treatment
Protoporphyrin Concentration in Blood
Timeframe: Samples collected while on treatment (range 93-208 treatment days)